#United States #New York #Faruqi & Faruqi #Josh Wilson #Aquestive Therapeutics

Investor Alert: Faruqi & Faruqi Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating possible claims relating to Aquestive Therapeutics, Inc. following troubling developments that have significantly impacted its stock performance. Investors who have faced substantial losses in their investments in Aquestive Therapeutics are encouraged to reach out to the firm for guidance on their legal options.

On January 29, 2026, shares of Aquestive Therapeutics experienced a dramatic decline of approximately 40% within a single trading day. This sudden drop came on the heels of an announcement from the U.S. Food and Drug Administration (FDA) indicating that there were deficiencies identified in the company's New Drug Application (NDA) for Anaphylm, a sublingual film designed to treat severe allergic reactions, including the risk of anaphylaxis. Such a disclosure raised alarms about the viability of the application as the FDA stated that these deficiencies were significant enough to halt discussions on labeling and post-marketing requirements, jeopardizing the approval timeline set for January 31, 2026.

The investigation led by Faruqi & Faruqi aims to uncover whether the company failed to disclose critical information that could affect investors' decisions and ultimately their financial outcomes. Concerned investors have been urged to contact James (Josh) Wilson, a senior partner at the firm, by calling 877-247-4292 or 212-983-9330 (Ext. 1310). Providing a robust path for investors to reclaim their interests, the firm is prepared to offer legal counsel and potential strategies for redress.

Faruqi & Faruqi, with a solid reputation in securities litigation, has successfully recovered hundreds of millions for investors since its inception in 1995. For more information regarding the ongoing investigation into Aquestive Therapeutics, interested parties can visit their dedicated webpage at faruqilaw.com/AQST or reach out directly to the firm for personalized assistance.

As the approval process for Anaphylm remains uncertain amid FDA scrutiny, investors watching Aquestive Therapeutics may seek to understand their legal rights thoroughly. With the firm's extensive background in addressing shareholder grievances, there lies a possibility for affected shareholders to reclaim losses in the incident's aftermath. Furthermore, updates on this investigation will be consistently shared through social media platforms such as LinkedIn, X, and Facebook, ensuring interested parties stay informed.

The investigation serves as a timely reminder of the importance of transparency in the pharmaceutical industry's regulatory processes and its direct impacts on investor confidence and stock valuations. As the situation unfolds, stakeholders will be keen to observe not only the outcomes of the current investigations but also how this aligns with investment strategies moving forward.

Additionally, Faruqi & Faruqi emphasizes that prior results do not guarantee similar outcomes in future cases, signifying the unpredictable nature of securities litigation. They remain open to discussing individual scenarios to provide strategic insights tailored to specific investor situations, ensuring that all communications are held confidentially.

In summary, the current predicament facing Aquestive Therapeutics underscores the paramount importance of diligent oversight in the pharmaceutical sector, as investor trust can quickly be eroded by regulatory setbacks. This investigation highlights the necessary interplay between corporate transparency and investor rights—for both protection and potential recovery in financial losses. Investors are advised to remain vigilant as further developments may emerge from this ongoing investigation.